FDA approval process questioned as it approves new early-stage $56K US/year treatment for Alzheimer’s despite its own panel founding insufficient evidence of efficacy. Only when company changed the study endpoint did it show efficacy compared to placebo.

Dr. Barry Dworkin

Medical Mythbusting Commentary for June 8, 2021

FDA approval process questioned as it approves new early-stage $56K US/year treatment for Alzheimer's despite its own panel founding insufficient evidence of efficacy. Only when company changed the study endpoint did it show efficacy compared to placebo. Play Now | Play in Popup | Download

Source:
In controversial decision, FDA approves first new Alzheimer’s disease drug in nearly 20 years

Related posts:

  1. Study indicates drug used for early Alzheimer Disease is helpful in later stages
  2. Very small electrical pacemaker brain stimulation study to treat Alzheimer memory damage is interesting but no conclusions can be drawn for now.
  3. Common medications are associated with diminish brain function and size.
  4. Study bias against methadone distribution clinics blinds them to the deficiencies of mental health cares services in Ontario
Bitnami